{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T11:17:48Z","timestamp":1788952668239,"version":"build-2803163510"},"reference-count":31,"publisher":"American Society of Hematology","issue":"11","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,6,13]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Cytarabine arabinoside (Ara-C) has been the cornerstone of acute myeloid leukemia (AML) chemotherapy for decades. After cellular uptake, it is phosphorylated into its active triphosphate form (Ara-CTP), which primarily exerts its cytotoxic effects by inhibiting DNA synthesis in proliferating cells. Interpatient variation in the enzymes involved in the Ara-C metabolic pathway has been shown to affect intracellular abundance of Ara-CTP and, thus, its therapeutic benefit. Recently, SAMHD1 (SAM and HD domain\u2013containing deoxynucleoside triphosphate triphosphohydrolase 1) has emerged to play a role in Ara-CTP inactivation, development of drug resistance, and, consequently, clinical response in AML. Despite this, the impact of genetic variations in SAMHD1 on outcome in AML has not been investigated in depth. In this study, we evaluated 25 single nucleotide polymorphisms (SNPs) within the SAMHD1 gene for association with clinical outcome in 400 pediatric patients with newly diagnosed AML from 2 clinical trials, AML02 and AML08. Three SNPs, rs1291128, rs1291141, and rs7265241 located in the 3\u2032 region of SAMHD1 were significantly associated with at least 1 clinical outcome: minimal residual disease after induction I, event-free survival (EFS), or overall survival (OS) in the 2 cohorts. In an independent cohort of patients from the COG-AAML1031 trial (n\u00a0= 854), rs7265241 A&amp;gt;G remained significantly associated with EFS and OS. In multivariable analysis, all the SNPs remained independent predictors of clinical outcome. These results highlight the relevance of the SAMHD1 pharmacogenomics in context of response to Ara-C in AML and warrants the need for further validation in expanded patient cohorts.<\/jats:p>","DOI":"10.1182\/bloodadvances.2022009088","type":"journal-article","created":{"date-parts":[[2023,1,23]],"date-time":"2023-01-23T16:14:11Z","timestamp":1674490451000},"page":"2538-2550","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":9,"title":["SAMHD1 single nucleotide polymorphisms impact outcome in children with newly diagnosed acute myeloid leukemia"],"prefix":"10.1182","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0789-1075","authenticated-orcid":false,"given":"Richard J.","family":"Marrero","sequence":"first","affiliation":[{"name":"1Department of Pharmacotherapy and Translational Research, College of Pharmacy, University of Florida, Gainesville, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueyuan","family":"Cao","sequence":"additional","affiliation":[{"name":"2Department of Health Promotion and Disease Prevention, University of Tennessee Health Science Center, Memphis, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiyun","family":"Wu","sequence":"additional","affiliation":[{"name":"3Department of Biostatistics, St. Jude Children\u2019s Research Hospital, Memphis, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdelrahman H.","family":"Elsayed","sequence":"additional","affiliation":[{"name":"1Department of Pharmacotherapy and Translational Research, College of Pharmacy, University of Florida, Gainesville, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffery M.","family":"Klco","sequence":"additional","affiliation":[{"name":"4Department of Pathology, St. Jude Children\u2019s Research Hospital, Memphis, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9956-5647","authenticated-orcid":false,"given":"Raul C.","family":"Ribeiro","sequence":"additional","affiliation":[{"name":"5Department of Oncology, St. Jude Children\u2019s Research Hospital, Memphis, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9885-3527","authenticated-orcid":false,"given":"Jeffrey E.","family":"Rubnitz","sequence":"additional","affiliation":[{"name":"5Department of Oncology, St. Jude Children\u2019s Research Hospital, Memphis, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaotu","family":"Ma","sequence":"additional","affiliation":[{"name":"6Department of Computational Biology, St. Jude Children\u2019s Research Hospital, Memphis, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soheil","family":"Meshinchi","sequence":"additional","affiliation":[{"name":"7Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7482-5644","authenticated-orcid":false,"given":"Richard","family":"Aplenc","sequence":"additional","affiliation":[{"name":"8Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. Anders","family":"Kolb","sequence":"additional","affiliation":[{"name":"9Nemours Center for Cancer and Blood Disorders, Alfred I. DuPont Hospital for Children, Wilmington, DE"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rhonda E.","family":"Ries","sequence":"additional","affiliation":[{"name":"7Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd A.","family":"Alonzo","sequence":"additional","affiliation":[{"name":"10Children's Oncology Group Statistics and Data Center, Monrovia, CA"},{"name":"11Biostatistics Division, University of Southern California, Los Angeles, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanley B.","family":"Pounds","sequence":"additional","affiliation":[{"name":"3Department of Biostatistics, St. Jude Children\u2019s Research Hospital, Memphis, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0411-0007","authenticated-orcid":false,"given":"Jatinder K.","family":"Lamba","sequence":"additional","affiliation":[{"name":"1Department of Pharmacotherapy and Translational Research, College of Pharmacy, University of Florida, Gainesville, FL"},{"name":"12University of Florida Health Cancer Center, University of Florida, Gainesville, FL"},{"name":"13Center for Pharmacogenomics and Precision Medicine, College of Pharmacy, University of Florida, Gainesville, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2023,6,2]]},"reference":[{"issue":"1","key":"2023061219031797000_bib1","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.pcl.2007.11.003","article-title":"Acute myeloid leukemia","volume":"55","author":"Rubnitz","year":"2008","journal-title":"Pediatr Clin North Am"},{"issue":"8","key":"2023061219031797000_bib2","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1038\/leu.2010.127","article-title":"Consequent and intensified relapse therapy improved survival in pediatric AML: results of relapse treatment in 379 patients of three consecutive AML-BFM trials","volume":"24","author":"Sander","year":"2010","journal-title":"Leukemia"},{"issue":"1","key":"2023061219031797000_bib3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/1097-0142(197001)25:1<1::AID-CNCR2820250102>3.0.CO;2-N","article-title":"Prolonged infusion of arabinosyl cytosine in childhood leukemia","volume":"25","author":"Wang","year":"1970","journal-title":"Cancer"},{"issue":"6","key":"2023061219031797000_bib4","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1038\/sj.leu.2402114","article-title":"Nucleoside analogues: mechanisms of drug resistance and reversal strategies","volume":"15","author":"Galmarini","year":"2001","journal-title":"Leukemia"},{"issue":"5","key":"2023061219031797000_bib5","doi-asserted-by":"crossref","first-page":"966","DOI":"10.3390\/cancers13050966","article-title":"Response and toxicity to cytarabine therapy in leukemia and lymphoma: from dose puzzle to pharmacogenomic biomarkers","volume":"13","author":"Di Francia","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"1","key":"2023061219031797000_bib6","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1124\/jpet.111.182873","article-title":"Genetic variants in cytosolic 5'-nucleotidase II are associated with its expression and cytarabine sensitivity in HapMap cell lines and in patients with acute myeloid leukemia","volume":"339","author":"Mitra","year":"2011","journal-title":"J\u00a0Pharmacol Exp Ther"},{"issue":"10","key":"2023061219031797000_bib7","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.2217\/pgs.09.118","article-title":"Genetic factors influencing cytarabine therapy","volume":"10","author":"Lamba","year":"2009","journal-title":"Pharmacogenomics"},{"issue":"2","key":"2023061219031797000_bib8","first-page":"250","article-title":"SAMHD1 is a biomarker for cytarabine response and a therapeutic target in acute myeloid leukemia","volume":"23","author":"Schneider","year":"2017","journal-title":"Nat\u00a0Med"},{"issue":"35","key":"2023061219031797000_bib9","doi-asserted-by":"crossref","first-page":"14272","DOI":"10.1073\/pnas.1312033110","article-title":"The deoxynucleotide triphosphohydrolase SAMHD1 is a major regulator of DNA precursor pools in mammalian cells","volume":"110","author":"Franzolin","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7377","key":"2023061219031797000_bib10","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/nature10623","article-title":"HIV-1 restriction factor SAMHD1 is a deoxynucleoside triphosphate triphosphohydrolase","volume":"480","author":"Goldstone","year":"2011","journal-title":"Nature"},{"issue":"9","key":"2023061219031797000_bib11","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1080\/15384101.2018.1480216","article-title":"The dNTP triphosphohydrolase activity of SAMHD1 persists during S-phase when the enzyme is phosphorylated at T592","volume":"17","author":"Tramentozzi","year":"2018","journal-title":"Cell Cycle"},{"issue":"3","key":"2023061219031797000_bib12","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s00109-021-02131-w","article-title":"SAMHD1 in cancer: curse or cure?","volume":"100","author":"Schott","year":"2022","journal-title":"J\u00a0Mol Med (Berl)"},{"issue":"7353","key":"2023061219031797000_bib13","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1038\/nature10117","article-title":"SAMHD1 is the dendritic- and myeloid-cell-specific HIV-1 restriction factor counteracted by Vpx","volume":"474","author":"Laguette","year":"2011","journal-title":"Nature"},{"issue":"7","key":"2023061219031797000_bib14","first-page":"829","article-title":"Mutations involved in Aicardi-Gouti\u00e8res syndrome implicate SAMHD1 as regulator of the innate immune response","volume":"41","author":"Rice","year":"2009","journal-title":"Nat\u00a0Genet"},{"issue":"2","key":"2023061219031797000_bib15","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1038\/nm.4265","article-title":"Targeting SAMHD1 with the Vpx protein to improve cytarabine therapy for hematological malignancies","volume":"23","author":"Herold","year":"2017","journal-title":"Nat Med"},{"issue":"11","key":"2023061219031797000_bib16","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1038\/s41408-018-0134-z","article-title":"Low-level expression of SAMHD1 in acute myeloid leukemia (AML) blasts correlates with improved outcome upon consolidation chemotherapy with high-dose cytarabine-based regimens","volume":"8","author":"Rassidakis","year":"2018","journal-title":"Blood Cancer J"},{"issue":"43","key":"2023061219031797000_bib17","first-page":"E10022","article-title":"The structural basis for cancer drug interactions with the catalytic and allosteric sites of SAMHD1","volume":"115","author":"Knecht","year":"2018","journal-title":"Proc\u00a0Natl Acad Sci U S A"},{"issue":"1","key":"2023061219031797000_bib18","doi-asserted-by":"crossref","first-page":"e0169052","DOI":"10.1371\/journal.pone.0169052","article-title":"Substrates and inhibitors of SAMHD1","volume":"12","author":"Hollenbaugh","year":"2017","journal-title":"PLoS One"},{"issue":"1","key":"2023061219031797000_bib19","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/s12967-018-1463-1","article-title":"Association of genetic polymorphisms in genes involved in Ara-C and dNTP metabolism pathway with chemosensitivity and prognosis of adult acute myeloid leukemia (AML)","volume":"16","author":"Zhu","year":"2018","journal-title":"J\u00a0Transl Med"},{"issue":"6","key":"2023061219031797000_bib20","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/S1470-2045(10)70090-5","article-title":"Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial","volume":"11","author":"Rubnitz","year":"2010","journal-title":"Lancet Oncol"},{"issue":"23","key":"2023061219031797000_bib21","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1200\/JCO.19.00327","article-title":"Clofarabine can replace anthracyclines and etoposide in remission induction therapy for childhood acute myeloid leukemia: the AML08 multicenter, randomized phase III trial","volume":"37","author":"Rubnitz","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"7","key":"2023061219031797000_bib22","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.3324\/haematol.2019.220962","article-title":"Bortezomib with standard chemotherapy for children with acute myeloid leukemia does not improve treatment outcomes: a report from the Children's Oncology Group","volume":"105","author":"Aplenc","year":"2020","journal-title":"Haematologica"},{"issue":"12","key":"2023061219031797000_bib23","doi-asserted-by":"crossref","first-page":"3679","DOI":"10.1182\/blood-2004-03-1154","article-title":"Gene expression profiling of pediatric acute myelogenous leukemia","volume":"104","author":"Ross","year":"2004","journal-title":"Blood"},{"issue":"6968","key":"2023061219031797000_bib24","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1038\/nature02168","article-title":"The International HapMap Project","volume":"426","author":"International HapMap Consortium","year":"2003","journal-title":"Nature"},{"issue":"7845","key":"2023061219031797000_bib25","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/s41586-021-03205-y","article-title":"Sequencing of 53,831 diverse genomes from the NHLBI TOPMed Program","volume":"590","author":"Taliun","year":"2021","journal-title":"Nature"},{"issue":"1","key":"2023061219031797000_bib26","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1080\/17460441.2020.1811672","article-title":"Pharmacological strategies to overcome treatment resistance in acute myeloid leukemia: increasing leukemic drug exposure by targeting the resistance factor SAMHD1 and the toxicity factor Top2\u03b2","volume":"16","author":"Herold","year":"2021","journal-title":"Expert Opin Drug Discov"},{"issue":"1","key":"2023061219031797000_bib27","doi-asserted-by":"crossref","first-page":"3475","DOI":"10.1038\/s41467-019-11413-4","article-title":"Selective inactivation of hypomethylating agents by SAMHD1 provides a rationale for therapeutic stratification in AML","volume":"10","author":"Oellerich","year":"2019","journal-title":"Nat Commun"},{"issue":"7","key":"2023061219031797000_bib28","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1038\/s41419-022-05023-0","article-title":"Stabilization of SAMHD1 by NONO is crucial for Ara-C resistance in AML","volume":"13","author":"Zhang","year":"2022","journal-title":"Cell Death Dis"},{"key":"2023061219031797000_bib29","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/1742-4690-9-86","article-title":"Identification and characterization of naturally occurring splice variants of SAMHD1","volume":"9","author":"Welbourn","year":"2012","journal-title":"Retrovirology"},{"key":"2023061219031797000_bib30","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.exphem.2017.05.001","article-title":"With me or against me: tumor suppressor and drug resistance activities of SAMHD1","volume":"52","author":"Herold","year":"2017","journal-title":"Exp Hematol"},{"issue":"11","key":"2023061219031797000_bib31","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1080\/15384101.2017.1314407","article-title":"SAMHD1 protects cancer cells from various nucleoside-based antimetabolites","volume":"16","author":"Herold","year":"2017","journal-title":"Cell Cycle"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/11\/2538\/2057011\/blooda_adv-2022-009088-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/11\/2538\/2057011\/blooda_adv-2022-009088-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,12]],"date-time":"2023-06-12T15:03:46Z","timestamp":1686582226000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/7\/11\/2538\/494211\/SAMHD1-single-nucleotide-polymorphisms-impact"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,2]]},"references-count":31,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,6,13]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2022009088","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,2]]}}}